Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03855293
Other study ID # Rhexis Protection Shield
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2, 2016
Est. completion date April 5, 2018

Study information

Verified date February 2019
Source Vienna Institute for Research in Ocular Surgery
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cataract surgery is one of the most frequently performed surgical procedures worldwide. Since the introduction of phacoemulsification to remove the cataractous lens, risk and complication rates of cataract surgery decreased significantly.

The phacoemulsification technique utilizes a high-intensity ultrasound energy for the fragmentation and emulsification of the lens. One of the main complications during phacoemulsification, is damaging of the endothelium due to contact with lens fragments of the nucleus following turbulent flow of irrigating solution, resulting in corneal damage, inflammation of the endothelium and corneal edema.

In this study we want to evaluate the effect of the anterior capsule, gained by capsular rhexis, as a corneal shield during phacoemulsification on the corneal endothelium.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date April 5, 2018
Est. primary completion date April 1, 2017
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Cataract

- Age 21 and older

- Written informed consent prior to surgery

- Moderate to severe nuclear or mixed cataract

Exclusion Criteria:

- Corneal pathologies

- Pregnancy

- Patients with an increased surgical risk (i.e. patients with pseudoexfoliation syndrome, patients with the potential risk of intra-operative floppy iris syndrome)

Study Design


Intervention

Procedure:
Rhexis protection shield
In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Prim. Prof. Dr. Oliver Findl, MBA

Outcome

Type Measure Description Time frame Safety issue
Primary endothelium cell loss Comparison of the lost endothelium cells in both groups 1 year
Secondary central corneal thickness Comparison of corneal thickness between both groups 1 year
See also
  Status Clinical Trial Phase
Completed NCT04547036 - Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent Implantation
Completed NCT05529485 - Quantification of Factors Influencing Endothelial Damage During Phacoemulsification
Not yet recruiting NCT05194891 - Endothelial Changes in Pseudoexfoliation Syndrome
Recruiting NCT05587205 - Study to Assess Safety and Tolerability of EO2002 Phase 1